abstract |
The present disclosure relates to an antibody that specifically binds CD38, capable of killing CD38 + cells by inducing apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. . The antibodies of the present disclosure can be used as a formulation or in manufacturing a formulation, and the antibody is administered to a human subject at a safe therapeutic dose of about 20 mg / kg or less. In one embodiment, the formulation is for the treatment of CD38 + multiple myeloma in humans. |